Article Sidebar

Submitted
Apr 26, 2021
Published
Apr 26, 2021
Download
PDF
Statistic
Read Counter : 46 Download : 41

Main Article Content

Abstract

Introduction


Adverse drug reactions (ADRs) are one of the leading causes of death in hospitalized patients. ADR is a response to a drug which is noxious, unintended and occurs at doses normally used in human for prophylaxis and treatment. Steven Johnson syndrome is an immune complex mediated hypersensitivity complex that typically involves the skin and mucous membranes. Steven Johnson syndrome and toxic epidermal necrolysis are rare (TEN 90% SJS less than 10% body surface area detachment) but life threatening cutaneous adverse drug reactions. Drugs like antiepileptics (Phenobarbitone, phenytoin, lamotrigine), antibiotics (penicillin, cephalosporins, sulphonamides) anti gout drug allopurinol are considered as one of the most common causative factor for these serious ADRs.


Discussion


A four year old girl, known epileptic for the last two years, has generalized idiopathic epilepsy. She had been on Sodium Valproate and well controlled. The mother stopped the Valproate having been seizure free for two years .Two weeks later she had a generalized seizure lasting for ten minutes. The mother consulted some other doctor who prescribed Phenobarbitone 20 mg twice daily. Two weeks later she developed a skin rash on the face which spread to the trunk, upper and lower limbs and lastly the mucous membrane of the mouth and genitalia. The rash was very itchy. She also complained of inability to swallow and burning micturition due to genital ulcers. She was admitted to pediatric intensive care unit (PICU) in tertiary care hospital.  The symptomatic and supportive treatment with corticosteroids and liquid paraffin was given for the initial management of SJS. Patient was discharged after 24days treatment.


Conclusion


By the withdrawal of the drug, the condition of the patient was improved. So the drug withdrawal is the first line for management of drug induced Steven Johnson syndrome.

Keywords

Adverse drug reactions epilepsy Steven Johnson syndrome

Article Details

How to Cite
Dr G. Ramya Bala Prabha, Manasa Bollampally, Vyshnavi kuarra, Sharadha Srikanth, & Dr.T. Rammohan reddy. (2021). Phenobarbitone induced steven johnson syndrome (SJS) Case report. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(4), 441-445. https://doi.org/10.61096/ijrpp.v4.iss4.2015.441-445
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Man CB, kwan P, Baurn L, Yu E, Lau KM, Cheng AS, Ng MH, Association between HLA-B*1502Allele and Antiepileptic Drug induced cutaneous reactions in Han Chinese Epilepsia 2007.48(5):1015-1018.
  2. [2]. Fitzpatrick’s dermatology in general medicine, Editors: Irwin m. Freeberg, Arthur Z. Eisen, Klans Wolff, K. Frank Austin, Lowell A. Goldsmith, Stephen I. Katz, 6th edition, Mc Graw Hill, 2003, page: 543-57.
  3. [3]. Lyell A: Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68: 355–361, 1956.
  4. [4]. Tennis P, Stern R. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-546.
  5. [5]. RoujeauJC, etal, Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
  6. [6]. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994; 331:1272-85.
  7. [7]. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, TouraineR :Toxic epidermal necrolysis: clinical findingsandprognosisfactorsin87patients.ArchDermatol 123: 1160–1165, 1987
  8. [8]. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC, EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2000; 15(14):1843-8.
  9. [9]. Roujeau JC. Steven-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24; 726-9.
  10. [10]. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome, does early withdrawal of causative drugs decrease the risk of death Arch Dermatol, 136, 2000, 323–327
  11. [11]. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Steven-Johnson syndrome and toxic epidermal necrolysis: A review of literature. Ann Allergy Asthma Immunol 2005; 94:419-36.
  12. [12]. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 14:333(24):1600-7.
  13. [13]. Roger walker, Cate whittlesea. Drug induced skin disorders SJS. Text book of Clinical pharmacy and therapeutics 4thedition 2007. Churchill Livingstone Elsevier, Pg. no. 811 12.
  14. [14]. AM Stevens, FC Johnson. A new eruptive fever associated with stomatitis and ophthalmia. Amer J Dis Child 1922; 24(6):526-33.
  15. [15]. Dinerman M. Stevens – Johnson Syndrome with Mycoplasma pneumonia and Enterovirus. International Pediatrics 2004;19(4): 237-9.
  16. [16]. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythemamultiforme. Arch Dermatol 1993; 129 (1):92-6.
  17. [17]. Schlienger RG, Shear NH: Antiepileptic drug hypersensitivity syndrome. Epilepsia 39(Suppl7): S3–S7, 1998
  18. [18]. Sladden M, Mortimer N, Chave T. Toxic epidermal caused bylamotrigine. Aust Fam Physician 2004; 33(10):829-30.
  19. [19]. Mixkonhaupt M, Messenheimer J. Tennis P, Schlingmann J. Risk for Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64(7):1134-8.
  20. [20]. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. TheLancet 1999; 535: 2190 – 2194
  21. [21]. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: A retrospective study of causative drugs and clinical Outcome. Indian J Dermatol Venereol Leprol 2008; 74:238-40.
  22. [22]. Saha K. Toxic epidermal necrolysis: Current concepts in pathogenesis and treatment. Indian J Dermatol Venereol Leprol 2000; 66:10-7.
  23. [23]. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008; 122:992–1000. [PubMed]
  24. [24]. Stevens Johnson Syndrome & Toxic Epidermal Necrolysis (http://dermnetnz.org/reaction /sjs-ten.html).